Notícias e Atividades da Storm Therapeutics

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Storm Therapeutics

• Jerry McMahon, Chief Executive Officer & President
• Paul Workman, Director
• Tony Kouzarides, Director

Criar um alerta
para seguir os movimentos de executivos da Storm Therapeutics.

Storm Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Storm Therapeutics

• STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• Events | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• Press releases | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• View more press releases Close

Redes sociais sobre Storm Therapeutics

• Storm Therapeutics na Wikipedia, Google News e Yahoo Finance
• Storm Therapeutics na LinkedIn, Twitter e YouTube